CM
Crestline Management’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-295,354
| Closed | -$7.46M | – | 117 |
|
|
2024
Q4 | $7.46M | Buy |
295,354
+157,366
| +114% | +$3.98M | 0.25% | 85 |
|
|
2024
Q3 | $4.69M | Buy |
137,988
+52,637
| +62% | +$1.79M | 0.24% | 110 |
|
|
2024
Q2 | $3.16M | Buy |
85,351
+16,062
| +23% | +$594K | 0.25% | 112 |
|
|
2024
Q1 | $2.91M | Buy |
69,289
+2,046
| +3% | +$85.9K | 0.26% | 111 |
|
|
2023
Q4 | $2.67M | Buy |
67,243
+4,133
| +7% | +$164K | 0.23% | 117 |
|
|
2023
Q3 | $1.74M | Buy |
63,110
+21,383
| +51% | +$588K | 0.2% | 113 |
|
|
2023
Q2 | $1.42M | Buy |
41,727
+11,465
| +38% | +$389K | 0.15% | 122 |
|
|
2023
Q1 | $1.09M | Sell |
30,262
-6,103
| -17% | -$220K | 0.13% | 121 |
|
|
2022
Q4 | $1.62M | Sell |
36,365
-3,628
| -9% | -$162K | 0.24% | 80 |
|
|
2022
Q3 | $1.12M | Buy |
39,993
+1,900
| +5% | +$53.4K | 0.15% | 104 |
|
|
2022
Q2 | $1.03M | Buy |
38,093
+5,998
| +19% | +$162K | 0.13% | 120 |
|
|
2022
Q1 | $1.09M | Buy |
+32,095
| New | +$1.09M | 0.13% | 131 |
|